Glaxo's China scandal ate into CEO's bonus; Martoma wants a new trial after insider trading conviction;

@FierceBiotech: Aventis spinout Scynexis plots a $55M IPO to push an ex-Merck. More | Follow @FierceBiotech

@JohnCFierce: Report: Novartis reorganization quietly claims 3,000 jobs in just 4 months. News | Follow @JohnCFierce

@DamianFierce: Bayer looks to boost its R&D budget to $15.5B over the next three years. News | Follow @DamianFierce

@EmilyMFierce: Brain cell communication plays role in regulating tau in Alzheimer's. Story | Follow @EmilyMFierce

> GlaxoSmithKline's ($GSK) China bribery scandal cost CEO Andrew Witty up to $410,000 in potential bonus money. Story

> Mathew Martoma, the ex-SAC fund manager convicted of insider trading, is asking a judge to toss that verdict and grant him a new trial, arguing that prosecutors failed to prove he obtained secret information before selling off shares of Wyeth and Elan. Article

> Perrigo is handing over ELND005, a former Elan treatment for Alzheimer's disease, to Transition Therapeutics ($TTHI) for an undisclosed sum, also making a $15 million investment in the biotech. More

Medical Device News

@FierceMedDev: Twisted fibers make low-cost artificial muscle to be used in robotics, prosthetics. Item | Follow @FierceMedDev

@MarkHFierce: VC options may have declined in the device and Dx worlds, but they're far from gone. See: Abingworth. Story | Follow @MarkHFierce

@MichaelGFierce: A tattoo to deliver a treatment for deadly sandfly-borne skin disease? It's a first. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Only 15 percent of all ovarian cancers are detected in early stages--but nVision Medical plans to change all that. Article | Follow @EmilyWFierce

> HeartWare's heart pump revenue jumped in Q4, thanks to U.S. growth. News

> Illumina's prenatal blood test shows standout results in NEJM. More

> S. Korea is trying to decide whether the Galaxy S5 is a medical device. Story

Pharma News

@FiercePharma: Best-read FP story yesterday: Eliquis earns best safety score in its class in analysis of FDA adverse event reports. Piece | Follow @FiercePharma

@TracyStaton: J&J's high-stakes argument against a $1.2B Risperdal fine begins in Arkansas' top court. News | Follow @TracyStaton

@EricPFierce: Mylan earnings get shot in the arm from epinephrine shortage. More | Follow @EricPFierce

@CarlyHFierce: Bayer's 2013 earnings are out. Release: More. BloombergNews' take: Article | Follow @CarlyHFierce

> GSK trims Witty's bonus in face of China probe. Story

> Endo loss widens, R&D chief departs amid regulatory struggles. Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.